ZA200601864B - Process for purifying mesotrione - Google Patents
Process for purifying mesotrione Download PDFInfo
- Publication number
- ZA200601864B ZA200601864B ZA200601864A ZA200601864A ZA200601864B ZA 200601864 B ZA200601864 B ZA 200601864B ZA 200601864 A ZA200601864 A ZA 200601864A ZA 200601864 A ZA200601864 A ZA 200601864A ZA 200601864 B ZA200601864 B ZA 200601864B
- Authority
- ZA
- South Africa
- Prior art keywords
- mesotrione
- enolate
- solution
- nmsba
- purification
- Prior art date
Links
- 239000005578 Mesotrione Substances 0.000 title claims description 151
- KPUREKXXPHOJQT-UHFFFAOYSA-N mesotrione Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)C)=CC=C1C(=O)C1C(=O)CCCC1=O KPUREKXXPHOJQT-UHFFFAOYSA-N 0.000 title claims description 151
- 238000000034 method Methods 0.000 title claims description 146
- 239000000243 solution Substances 0.000 claims description 82
- 239000012535 impurity Substances 0.000 claims description 58
- 229910052799 carbon Inorganic materials 0.000 claims description 51
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 50
- 238000011282 treatment Methods 0.000 claims description 49
- 238000000746 purification Methods 0.000 claims description 44
- 238000004821 distillation Methods 0.000 claims description 38
- 238000002425 crystallisation Methods 0.000 claims description 23
- 238000001179 sorption measurement Methods 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 16
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 claims description 13
- 238000010908 decantation Methods 0.000 claims description 13
- -1 enol ester Chemical class 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 12
- 230000008707 rearrangement Effects 0.000 claims description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 11
- 229910052700 potassium Inorganic materials 0.000 claims description 11
- 239000011591 potassium Substances 0.000 claims description 11
- SKDDBIWRHFHMKM-UHFFFAOYSA-N 4-methylsulfonyl-2-nitrobenzoyl chloride Chemical compound CS(=O)(=O)C1=CC=C(C(Cl)=O)C([N+]([O-])=O)=C1 SKDDBIWRHFHMKM-UHFFFAOYSA-N 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 230000003647 oxidation Effects 0.000 claims description 8
- 238000007254 oxidation reaction Methods 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 6
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 111
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 63
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 46
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 238000010561 standard procedure Methods 0.000 description 15
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 9
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- 239000003463 adsorbent Substances 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000011045 prefiltration Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000006462 rearrangement reaction Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003021 water soluble solvent Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- OXBDLEXAVKAJFD-UHFFFAOYSA-N 1-methyl-4-methylsulfonyl-2-nitrobenzene Chemical compound CC1=CC=C(S(C)(=O)=O)C=C1[N+]([O-])=O OXBDLEXAVKAJFD-UHFFFAOYSA-N 0.000 description 1
- QNOUABMNRMROSL-UHFFFAOYSA-N 110964-79-9 Chemical compound CS(=O)(=O)C1=CC=C(C(O)=O)C([N+]([O-])=O)=C1 QNOUABMNRMROSL-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Description
PROCESS POR PURIFYING MESOTRIONE
The present invention relates to a novel process for reducing the level of impurities in a mesotrione sample.
Mesotrione (22 -nitro-4’-methylsulphonyl benzoyl)-1,3-cyclohexanedione) isa selective com herbicide and has the structure of formula (I) 0 0] NO, oO SO,CH,
Mesotrione is prepared by reacting 2-nitro-4-methylsulphonyl benzoyl chloride with cyclohexanedione to give the enol ester, followed by a rearrangement reaction to give mesotrione, as shown in the following reaction scheme:
OCI
NO, + + (CHCH)N Solvent
SO,CH, ° 0]
NO, O HO 1% 8 : H,C>—CN 0] HC
TT CHO o o CHO: er 2-Nitro-4-methylsulphonyl benzoyl chloride (NMSBC) is prepared from the corresponding 2-nitro-4-methylsulphonyl benzoic acid (NMSBA), which in turn is prepared by oxidation of 2-nitro-4-methylsulphonyl toluene (NMST). More details on the preparative route may be found in US4695673.
However, we have found that this process generally results in undesirable level of impurities being present in the final mesotrione product. One method we have found of reducing the impurities is to subject the NMSBA to a purification process before converting to NMSBC, as described in more detail in W002/076934. However, purifying the NMSBA does not always guarantee that the final product is free from, or has sufficiently low levels of, these impurities.
It is therefore an object of the present invention to provide an improved process for reducing the level of impurities in a mesotrione sample.
Accordingly, the present invention provides a process for reducing the levels of impurities in a mesotrione sample, said process comprising the steps of: @) forming a mesotrione enolate solution in an aqueous solvent, (ii) carmying out one or more purification processes, and (iii) crystallising the purified mesotrione out of solution.
Optionally, the process may further comprise a distillation step, which is suitably carried out prior to forming the mesotrione enolate. Generally, the distillation step will only, although not necessarily, be used if the mesotrione product has not been isolated after its preparation.
The enolate solution may be formed by the addition of an appropriate base, for example NaOH, KOH, NH,OH, pyridine or triethylamine; suitably the enolate is formed by the addition of NaOH or KOH. Suitably, the aqueous solvent is water, although in some cases an additional solvent, for example acetonitrile, methanol, ethanol, acetone, dimethylformamide etc, may be required to ensure complete dissolution of the mesotrione enolate. The mesotrione enolate solution is suitably formed at a pH of 6-13.
The one or more purification processes may be selected from the following: (a) filtration, (b) adsorption with suitable sorbent, such as carbon, clay etc., (c) extraction with an organic solvent, or (d) decantation.
Any number of the purification processes may be carried out and they may be performed in any order. Suitably, at least two purification processes are carried out and preferably at least three. The purification processes will now be described in further detail.
Filtration is carried out to remove any insoluble impurities that remain in the mesotrione enolate solution. The filtration may be carried out by any suitable method known in the art to a skilled person.
Adsorption treatment adsorbs impurities from the mesotrione enolate solution. A mesotrione enolate solution of suitably 1-30%, and preferably 8-11% is contacted with carbon in a batch or continuous fashion for a period of several hours. Concentration of the adsorbent solution relative to the concentration of mesotrione in the enolate is suitably 2- 40% and preferably 10-20%. The pH for adsorption treatment is suitably between pH 5 and 13, and preferably between pH 9 and 11.
Extraction with an organic solvent is carried out to remove any impurities, which are soluble in the organic phase but insoluble in the aqueous phase. An organic solvent is added to the mesotrione enolate aqueous solution and some impurities will preferentially dissolve in the organic phase which is then removed and discarded. The mesotrione enolate aqueous solution may be ‘washed’ a number of times with organic solvent, such as once, twice, three times, four times etc or continuously contacted in a counter current column. It is unlikely that more than four ‘washings’ would be required as all the impurities soluble in the organic solvent are likely to have been removed after this number of ‘washings’. Suitable organic solvents will be known to those skilled in the art, but may include benzonitrile, acetonitrile/xylene, xylene, methylene chloride, MIBK, ethyl ether, n-hexane and 1,2- dichloroethane.
Decantation simply refers to the removal of any organic solvent from the solution.
Organic solvent is likely to remain with the mesotrione enolate aqueous solution if the mesotrione product has not been isolated after its preparation and no distillation step is carried out. Removal of the organic solvent will remove any impurities soluble in the organic solvent, but insoluble in the aqueous solution.
The optional distillation step is suitably carried out prior to forming the mesotrione enolate solution and will remove any organic solvent remaining after the condensation/rearrangement reaction described above.
The crystallisation step may be carried out by any method known to those skilled in the art. For example, the process may be a batch method, a semi-batch method or a- continuous crystallisation method. The crystallisation is suitably effected by reducing the pH of the mesotrione enolate solution, for example by the controlled addition of acid such as hydrochloric acid. Seed crystals of mesotrione may be used to assist the crystallisation process. Optionally, a water-soluble solvent may be added, since the presence of a water soluble solvent such as acetonitrile aids in reducing the amount of impurities present at this point. _
In one specific embodiment of the invention, the process comprises: a distillation step; formation of a mesotrione enolate solution, preferably the potassium enolate; one or more purification steps; and crystallisation of mesotrione.
In a second specific embodiment of the invention, the process comprises: formation of a mesotrione enolate solution, preferably the potassium enolate; decantation, filtration and adsorption treatment, carried out in any order (although preferably the decantation process is carried out first); and crystallisation of mesotrione.
By carrying out the process according to the invention, the level of impurities in the final mesotrione product is reduced to an acceptable level.
A further advantage of the process of the present invention is that is can be integrated into the mesotrione manufacturing process, thus eliminating the need for isolation of crude mesotrione followed by purification. Accordingly, a further aspect of the invention provides an integrated manufacturing/purification process for mesotrione, said process comprising the steps of: @) reacting cyclohexanedione with 2-nitro-4-methylsulphonyl benzoyl! chloride (NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; (ii) formation of mesotrione enolate in aqueous solution; (ili) carrying out one or more purification processes, and (iv) crystallising the purified mesotrione ouit of solution.
Optionally, the process may further comprise a distillation step, which is suitably carried out prior to forming the mesotrione enolate.
Optionally, the NMSBC is first subjected to a carbon purification treatment.
Thus, one specific embodiment of this aspect of the invention provides an integrated manufacturing/purification process for mesotrione, said process comprising: reacting cyclohexanedione with 2-nitro-4-methylsulphonyl benzoyl chloride (NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; a distillation step;
formation of potassium enolate mesotrione solution; one or more purification steps; and crystallisation of mesotrione.
A second specific embodiment of this aspect of the invention provides an integrated manufacturing/purification process for mesotrione, said process comprising reacting 5 cyclohexanedione with 2-nitro-4-methylsulphonyl benzoyl chloride (NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; formation of a mesotrione enolate solution, preferably the potassium enolate; decantation, filtration and adsorption treatment, carried out in any order (although preferably the decantation process is carried out first); and crystallisation of mesotrione.
Previously, in order to attempt to obtain a final mesotrione product with an acceptable level of impurities, it was necessary to subject the crude NMSBA (prepared by oxidation of NMST) to a purification process, as described in W002/076934. However, as "mentioned above, this did not always give sufficiently low levels of impurities in the final mesotrione product to be acceptable. Surprisingly, we have now found that if the process of the invention is followed, the purification of NMSBA is not essential or at most only ‘partial’ purification, such as one step as opposed to the two or three disclosed in
W002/076934, is required; that is acceptable levels of impurities can be obtained in the final mesotrione product when less purified or even crude NMSBA is used. Accordingly, a yet further aspect of the invention provides a process for preparing mesotrione, said method comprising: @) Oxidation of NMST to give crude NMSBA; (ii) conversion of NMSBA to NMSBC; (iii) reacting cyclohexanedione with 2-nitro-4-methylsulphonyl benzoyl chloride (NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; (iv) formation of mesotrione enolate in aqueous solution; (v) carrying out one or more purification processes, and (vi) crystallising the purified mesotrione out of solution.
Optionally, the process may further comprise partial purification of crude NMSBA.
Optionally, the process may further comprise a distillation step, which is suitably carried out prior to forming the mesotrione enolate.
Thus one specific embodiment of this aspect of the invention provides a process for preparing mesotrione, said process comprising: oxidation of NMST to give crade NMSBA; optional partial purification of crude NMSBA; conversion of NMSBA to NMSBC; reacting cyclohexanedione with 2._nitro-4-methylsulphonyl benzoyl chloride (NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; 8 distillation step; formation of mesotrione enolate solution, preferably the potassium enolate; one or more purification steps; and crystallisation of mesotrione.
A second embodiment of this aspect of the invention provides a process for preparing mesotrione, said process comprising: oxidation of NMST to give crude NMSBA,; optional partial purification of crude NMSBA; conversion of NMSBA to NMSBC; reacting cyclohexanedione with 2-nitro-4-methylisulphonyl benzoyl chloride NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; formation of a mesotrione enolate solution; decantation, filtration and adsorption treatment carried out in any order; and crystallisation of mesotrione.
The present invention will now be described further by way of example only.
Example 1
This is an example of the solid adsorption treatment (using carbon as adsorbent) of previously isolated mesotrione which had high levels of impurities. The additional purification option of pre-filtration was used in these examples.
Example | Treatment Original | Impurities | %
No. Impurities | Content Reduction
Content after in
PPM) Treatment | Impurities
PP Content 1A Already isolated mesotrione was dissolved | 7900 2800 65% into a 10 % enolate solution at pH 9.5 with
KOH. The mixture was pre-filtered and contacted with 15 % carbon for 2.5 hours before being filtered and batch crystallized following standard lab procedures. 1B Already isolated mesotrione was dissolved | 7400 4500 39% into a 10 % enolate solution at pH 9.5 with
KOH. The mixture was pre-filtered and contacted with 15 % carbon for 2.5 hours before being filtered and batch crystallized following standard lab procedures. 1C Already isolated mesotrione was dissolved | 7400 69 % into a 10 % enolate solution at pH 9.5 with
NaOH/acetonitrile. The enolate was pre- filtered and contacted with 15 % carbon for 2.5 hours before being filtered and batch crystallized following standard lab procedures. iD Already isolated mesotrione was dissolved | 8800 78 % into a 10 % enolate solution at pH 9.5 with
NaOH/acetonitrile. The enolate was pre- filtered and batch carbon treated with 9 % carbon for 3 hours. The carbon was filtered and the enolate was crystallized in a continuous reactor following standard lab 1E Already isolated mesotrione was dissolved | 8800 3100 65% into a 10 % enolate solution at pH 9.5 with triethylamine. The enolate was pre-filtered and batch carbon treated with 9 % carbon for 3 hours. The carbon was filtered and : the enolate was crystallized in a continuous reactor following standard lab procedures.
IF Already isolated mesotrione was dissolved 7900 4600 42% into a 10 % enolate solution at pH 9.5 with
NaOH/acetonitrile. The mixture was pre- filtered and contacted with 15 % carbon for 2.5 hours before being filtered and batch crystallized following standard lab procedures. 1G Already isolated mesotrione was dissolved | 7400 38% into a 10 % enolate solution at pH 9.5 with :
NaOH. The mixture was pre-filtered and contacted with 15 % carbon for 2.5 hours before being filtered and batch crystallized following standard lab procedures.
Example 2
This is an example of a solvent extraction treatment of previously isolated mesotrione which had high levels of impurities.
Example | Treatment Original | Impurities | %
No. Impurities | Content | Reduction
Content after in (PPM) Treatment | Impurities
PP Content 2A Already isolated mesotrione was dissolved | 8000 49 % into a 10 % enolate solution at pH 12.5 with KOH. The mixture was contacted with 1,2-dichloroethane, the 1,2- dichloroethane was extracted, and the remaining aqueous layer was batch crystallized following standard lab
DIrocCedures.
Already isolated mesotrione was dissolved | 8000 46 % into a 10 % enolate solution at pH 12.5 with KOH. The mixture was contacted with benzonitrile, the benzonitrile was extracted, and the remaining aqueous layer was batch crystallized following standard lab procedures.
Example 3
This is an example of an integrated adsorption treatment of in-process mesotrione enolate. NMSBA purified by standard procedures was used as the starting material. The mixture was distilled before the enolate treatments and the purification element of pre- filtration was included. Different adsorbent loadings are shown in the examples in this table.
Example | Treatment Original | Impurities | %
No. Impurities { Content Reduction
Content after in (PPM) Treatment | Impurities
PP! Content 3A Mesotrione was made using the standard 13800 20% process from NMSBA purified by standard procedures. After the distillation, an enolate solution at pH 9.5 was formed with
KOH. The mixture was pre-filtered and contacted with 13 % carbon for 2 hours before being filtered and batch crystallized following standard lab procedures.
3B Mesotrione was made using the standard 13800 63 % process from NMSBA purified by standard procedures. After the distillation, an. enolate solution at pH 9.5 was formed with
KOH. The mixture was pre-filtered and contacted with 27 % carbon for 3.5 hours before being filtered and batch crystallized following standard lab procedures. . 3C Mesotrione was made using the standard 13800 5700 59% : process from NMSBA purified by standard procedures. After the distillation, an enolate solution at pH 9.5 was formed with :
KOH. The mixture was pre-filtered and contacted with 40 % carbon for 2 hours before being filtered and batch crystallized following standard lab procedures.
Mesotrionc was made using the standard 13800 5800 58% process from NMSBA purified by standard procedures. After the distillation, an enolate solution at pH 9.5 was formed with
KOH. The mixture was pre-filtered and contacted with 53 % carbon for 2 hours before being filtered and batch crystallized following standard lab procedures.
Mesotrione was made using the standard 17900 15900 11% process from NMSBA purified by standard procedures. After the distillation, an enolate solution at pH 9.5 was formed with
KOH. The mixture was pre-filtered and contacted with 5 % carbon for 2 hours : before being filtered and batch crystallized following standard lab procedures. 3F Mesotrione was made using the standard 17900 15000 16 % process from NMSBA purified by standard procedures. After the distillation, an "| enolate solution at pH 9.5 was formed with
KOH. The mixture was pre-filtered and contacted with 10 % carbon for 2 hours before being filtered and batch crystallized ‘ following standard lab procedures. 3G Mesotrione was made using the standard 17900 12300 31% process from NMSBA purified by standard procedures. After the distillation, an enolate solution at pH 9.5 was formed with
KOH. The mixture was pre-filtered and contacted with 20 % carbon for 2 hours before being filtered and batch crystallized following standard lab procedures.
Example 4
This is an example of an integrated adsorption treatment of in process mesotrione enolate. NMSBA purified by standard procedures was used as the starting material. The s mixture was distilled before the enolate treatment, and the purification element of pre- filtration was included. Different filtration conditions are used in the examples in this table.
Example | Treatment Original | Impurities | %
Noe. Impurities: | Content Reduction
Content after in (PPM) Treatment | Impurities
PP Content 4A Mesotrione was made using the standard 15800 7400 53% process from NMSBA purified by standard procedures. After the distillation, an enolate solution at pH 7 was formed with
KOH. The mixture was pre-filtered and : contacted with 10 % carbon for 2 hours before being filtered and batch crystallized following standard lab procedures. 4B Mesotrione was made using the standard 15800 7700 51% process from NMSBA purified by standard procedures. After the distillation, an enolate solution at pH 7 was formed with
KOH. The mixture was pre-filtered and contacted with 10 % carbon for 2 hours before being filtered and batch crystallized following standard lab procedures. 4C Mesotrione was made using the standard 15800 10400 34% - process from NMSBA purified by standard procedures. After the distillation, an enolate solution at pH 9.5 was formed with ‘| KOH. The mixture was pre-filtered and contacted with 10 % carbon for 2 hours before being filtered and batch crystallized following standard lab procedures.
Mesotrione was made using the standard 15800 8600 46 % process from NMSBA purified by standard procedures. After the distillation, an i enolate solution at pH 9.5 was formed with
KOH. The mixture was pre-filtered and contacted with 10 % carbon for 2 hours before being filtered and batch crystallized following standard lab procedures.
Example 5
This is an example of an integrated solvent extraction treatment of in process mesotrione enolate. Crude NMSBA was used as the starting material. The mixture was distilled before the enolate treatment.
Table 5
Example | Treatment Original | Impurities | %
No. Impurities | Content Reduction
Content after in
PPM) Treatment | Impurities
PP Content 5A Mesotrione was made using the standard 7800 29% process from crude NMSBA. After the distillation, an enolate solution at pH 13 was formed with KOH. The mixture was contacted with 1,2-dichloroethane, the 1,2- dichloroethane was extracted, and the : remaining aqueous layer was batch crystallized following standard lab procedures.
Example 6 ~ This is an example of an integrated adsorption treatment of in process mesotrione enolate. Partially purified NMSBA was used as the starting material. The mixture was distilled before the enolate treatment.
Table 6
Example | Treatment Original | Impurities | %
No. Impurities | Content | Reduction
Content after in (PPM) Treatment | Impurities
PP Content 6A Mesotrione was made using the standard 13300 6300 53% process from partially purified NMSBA .
After the distillation, an enolate solution at pH 5 was formed with NaOH and ACN.
The mixture was contacted with 20 % carbon for 2 hours before being filtered and batch crystallized following standard lab nrocedures.
Mesotrione was made using the standard 8500 4900 42% process from partially purified NMSBA(.
After the distillation, an enolate solution at pH 9 was formed with NaOH and ACN. :
The mixture was contacted with 20 % : carbon for 2 hours before being filtered and batch crystallized following standard lab procedures.
Example 7
This is an example of an integrated column adsorption treatment of in process mesotrione enolate. Crude NMSBA was used as the starting material. The mixture was distilled before the enolate treatment.
Example | Treatment Original | Impurities | %
No. Impurities | Content Reduction
Content after in (PPM) Treatment | Impurities
PP Content
TA Mesotrione was made from crude NMSBA 10500 8% following standard lab procedures. After the distillation, an enolate solution at pH 9.5 was formed with KOH. The mixture was pre-filtered and sent through a carbon column such that there was 14.9 % carbon usage. Samples were batch crystallized following standard lab procedures.
Mesotrione was made from crude NMSBA | 11400 11% following standard lab procedures. After the distillation, an enolate solution at pH 9.5 was formed with KOH. The mixture was pre-filtered and sent through a carbon column such that there was 5.08 % carbon usage. Samples were batch crystallized following standard lab procedures. 7C Mesotrione was made from crude NMSBA 6600 42% following standard lab procedures. After the distillation, an enolate solution at pH
9.5 was formed with KOH. The mixture was pre-filtered and sent through a carbon column such that there was 2.93 % carbon usage. Samples were batch crystallized following standard lab procedures.
Example 8
This is an example of an integrated adsorption treatment of in process mesotrione enolate. Purified or crude NMSBA was used as the starting material. TEA decantation is . included as a purification element. The mixture was distilled before the enolate treatment.
Example | Treatment Original | Impurities | %
No. Impurities | Content Reduction
Content after in (PPM) Treatment | Impurities : PP Content 8A Mesotrione was made from crude NMSBA | 51% by the standard process . An enolate solution at pH 13 was formed with KOH.
The TEA was decanted, and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab procedures. 8B Mesotrione was made from crude NMSBA | 20600 8900 57% by the standard process. After the distillation, an enolate solution at pH 13 was formed with KOH. The TEA was decanted, and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab procedures. 8C Mesotrione was made from crude NMSBA { 15000 6300 58% by the standard process. After the distillation, an enolate solution at pH 13 was formed with KOH. The TEA was decanted, and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab procedures.
NMSBA by the standard process . An enolate solution at pH 13 was formed with
KOH. The TEA was decanted, and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab procedures.
Mesotrione was made from purified 7300 60%
NMSBA by the standard process . An enolate solution at pH 13 was formed with
KOH after the completion of the solvent distillation. The TEA was decanted, and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab procedures.
Mesotrione was made from purified 6600 3300 50%
NMSBA by the standard process . An enolate solution at pH 13 was formed with
KOH after the completion of the solvent distillation. The TEA was decanted, and . the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab procequres.-
Example 9
This is an example of the effect of the presence of acetonitrile during crystallization on the impurity content of mesotrione. An integrated purification was done which used the purification elements of TEA decant and the presence of acetonitrile during the crystallization. The mixture was distilled before the enolate treatment. Crude NMSBA was used as the starting material.
Example | Treatment Original | Impurities | %
No. Impurities | Content Reduction
Content after in ‘ (PPM) Treatment | Impurities
PP Content 9A Mesotrione was made from crude NMSBA | 21800 12800 41% using the standard process. After solvent pH 13 was made and the TEA was decanted. The enolate was batch crystallized following standard lab procedures except that acetonitrile was present during the crystallization.
Mesotrione was made from crude NMSBA | 21800 12800 41% using the standard process. After solvent distillation, a potassium enolate solution at pH 13 was made and the TEA was decanted. The enolate was batch crystallized following standard lab procedures except that acetonitrile was present during the crystallization. 9C Mesotrione was made from crude NMSBA | 30900 9000 71% using the standard process. After solvent distillation, a potassium enolate solution at pH 13 was made and the TEA was decanted. The enolate was batch crystallized following standard lab procedures except that acetonitrile was present during the crystallization.
Example 10 :
This is an example of the integrated process starting with crude NMSBA in which a partial NMSBA purification is incorporated directly into the process. The purification elements of decantation and adsorption treatment are used in these examples.
Example | Treatment Original Impurities | %
No. Impurities | Content Reduction
Content after in (PPM) Treatment | Impurities
PP Content 10A Mesotrione was made from the integrated | 2900 2500 - 53% : process starting with crude NMSBA in water which was partially purified and distilled to remove water. Benzonitrile was added to make a NMSBA solution and the remaining water was distilled. Inorganic salts were filtered from the acid chloride after excess phosgene removal. The C/R : proceeded by normal reaction conditions.
An enolate solution at pH 13 was formed with KOH. The TEA and benzonitrile :
were decanted and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab procedures.
Mesotrionc was made from the integrated | 2900 62% process starting with crude NMSBA in water which was partially purified and distilled to remove water. Benzonitrile was added to make a NMSBA solution and the : remaining water was distilled. Inorganic salts were filtered from the acid chloride after excess phosgene removal. The C/R proceeded by normal reaction conditions.
An enolate solution at pH 13 was formed with KOH. The TEA and benzonitrile were decanted and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab 10C Mesotrione was made from the integrated | 2900 2100 28% process starting with crude NMSBA in water which was partially purified and distilled to remove water. Benzonitrile was added to make a NMSBA solution and the remaining water was distilled. Inorganic salts were filtered from the acid chloride after excess phosgene removal. The C/R proceeded by normal reaction conditions.
An enolate solution at pH 13 was formed with KOH. The TEA and benzonitrile were decanted and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab procedures.
Mesotrione was made from the integrated 1600 45% process starting with crude NMSBA in water which was partially purified and distilled to remove water. Benzonitrile was added to make a NMSBA solution and the remaining water was distilled. Inorganic salts were filtered from the acid chloride after excess phosgene removal. The C/R proceeded by normal reaction conditions.
An enolate solution at pH 13 was formed with KOH. The TEA and benzonitrile were decanted and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab procequres. ‘Mesotrione was made from the integrated | 2900 34% process starting with crude NMSBA in water which was partially purified and distilled to remove water . Benzonitrile was added to make a NMSBA solution and the remaining water was distilled. .
Inorganic salts were filtered from the acid chloride after excess phosgene removal.
The C/R proceeded by normal reaction conditions. An enolate solution at pH 13 was formed with KOH. The TEA and benzonitrile were decanted and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and ‘batch crystallized following standard lab procedures. 10F Mesotrione was made from the integrated | 2900 1500 48 % process starting with crude NMSBA in water which was partially purified and distilled to remove water at pH 0.8.
Benzonitrile was added to make a 20 %
NMSBA solution and the remaining water was distilled. Inorganic salts were filtered from the acid chloride after excess phosgene removal. The C/R proceeded by normal reaction conditions. An enolate solution at pH 13 was formed with KOH. :
The TEA and benzonitrile were decanted and the enolate was contacted with 20 % : carbon for 2 hours at pH 13 before being filtered and batch crystallized following standard lab procedures. 10G Mesotrione was made from the integrated | 4900 3100 37% process starting with crude NMSBA in water which was partially purified and distilled to remove water . Benzonitrile was added to make a NMSBA solution and the remaining water was distilled.
Inorganic salts were filtered from the acid chloride after excess phosgene removal.
The C/R proceeded by normal reaction conditions. An enolate solution at pH 13 was formed with KOH. The TEA and benzonitrile were decanted and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab
D rocedures. .
Mesotrione was made from the integrated 2500 22% process starting with crude NMSBA in water which was partially purified and distilled to remove water. Benzonitrile was added to make NMSBA solution and the remaining water was distilled. organic salts were filtered from the acid chloride after excess phosgene removal. The C/R proceeded by normal reaction conditions.
An enolate solution at pH 13 was formed with KOH. The TEA and benzonitrile were decanted and the enolate was contacted with 20 % carbon for 2 hours at : pH 9.5 before being filtered and batch crystallized following standard lab procedures.
Mesotrione was made from the integrated | 3200 38% process starting with crude NMSBA in water which was partially purified and distilled to remove water. Benzonitrile was added to make a NMSBA solution and the remaining water was distilled. Inorganic salts were filtered from the acid chloride after excess phosgene removal. The C/R proceeded by normal reaction conditions.
An enolate solution at pH 13 was formed with KOH. The TEA and benzonitrile were decanted and the enolate was contacted with 20 % carbon for 2 hours at pH 9.5 before being filtered and batch crystallized following standard lab procedures.
Example 11
Previously isolated mesotrione, made from crude NMSBA, was dissolved by addition of dilute potassium hydroxide to form a 9.1% w/w solution of potassium enolate at pHs 7,9.5 and 11, respectively. The very small amount of residual solid was removed by filtration.
Extraction
The aqueous solution of potassium enolate of mesotrione (183g) was extracted with solvent (150m) four times. The phases were separated after each extraction and the solvent phase was discarded. After the fourth extraction, the mesotrione was recovered from the aqueous phase by continuous crystallisation according to standard procedure. Analysis showed reduction of the impurities (Table 11A). The figures in parenthesis are the percentage of the impurities remaining after treatment. soe
Ter | eos | Awe
Adsorption
The aqueous solution of potassium enolate of mesotrione (183g) was stirred with 5g adsorbent at ambient temperature (~25°C) for 30 minutes. The adsorbent was removed by filtration and the mesotrione was recovered from the aqueous phase by continuous crystallisation according to standard procedure. Analysis showed reduction of the impurities (Table 11B). The figures in parenthesis are the percentage of the impurities remaining after treatment.
oo
Table 11B
Sum of impurities in mesotrione sample (%)
Ambersorb 348F 5.627 0.383 (6.81%) | 0.680 (12.1%) | 0.171 (3.04%)
Amberlite XAD4 -5.627 0.892 (15.9%) | 1.692 (30.1%)
Amberlite XAD16 0.245 (7.17%) | 0.063 (1.84%) | 0.145 (4.24%)
Molecular sieves SA 5.627 1.414 (25.1%) ] 1.792 (31.8%)
Claims (15)
1. A process for reducing the levels of undesirable impurities in a mesotrione sample, said process comprising the steps of: @) forming a mesotrione enolate solution in an aqueous solvent, : (if) carrying out one or more purification processes, and (iii) crystallising the purified mesotrione out of solution.
2. A process according to claim 1, wherein the process further comprises a distillation step.
3. A process according to claim 1 or 2, wherein the one or more purification processes are selected from the group consisting of filtration, adsorption treatment, extraction with an organic solvent, and decantation.
4. A process for reducing the levels of undesirable impurities in a mesotrione sample, said process comprising: a distillation step, formation of a mesotrione enolate ‘ solution; one or more purification steps; and crystallisation of mesotrione.
5. A process for reducing the levels of undesirable impurities in a mesotrione sample, said process comprising: formation of a mesotrione enolate solution; decantation, filtration and adsorption treatment carried out in any order; and crystallisation of mesotrione.
6. An integrated manufacturing/purification process for mesotrione, said process comprising the steps of: (i) reacting cyclohexanedione with 2-nitro-4-methylsulphonyl benzoyl chloride (NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; (ii) formation of mesotrione enolate in aqueous solution;
(iif) carrying out one or more purification processes, and (iv) crystallising the purified mesotrione out of solution.
7. A process according to claim 6, wherein said process further comprises a distillation step.
8. A process according to claim 6 or 7, wherein the NMSBC is first subjected to a carbon purification treatment.
09. An integrated manufacturing/purification process for mesotrione, said process comprising: reacting cyclohexanedione with 2-nitro-4-methylsulpbonyl benzoyl chloride (NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; a distillation step; formation of a mesotrione enolate solution; one or more purification steps; and crystallisation of mesotrione.
10. An integrated manufacturing/purification process for mesotrione, said process comprising reacting cyclohexanedione with 2-nitro-4-methylsulphonyl benzoyl chloride (NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; formation of a mesotrione enolate solution; decantation, filtration and adsorption treatment, carried out in any order; and crystallisation of mesotrione.
11. A process for preparing mesotrione, said method comprising: i) Oxidation of NMST to give crude NMSBA; (ii) conversion of NMSBA to NMSBC; (iii) reacting cyclohexanedione with 2-nitro-4-methylsulphonyl benzoyl chloride (NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; (iv) formation of mesotrione enolate in aqueous solution; (v) carrying out one or more purification processes, and (vi) crystallising the purified mesotrione out of solution.
12. The method of claim 11, wherein the process further comprises partial purification of the crude NMSBA.
13. The method of claim 11 or 12, wherein the process further comprises a distillation step.
14. A process for preparing mesotrione, said process comprising: oxidation of NMST to give crude NMSBA;; optional partial purification of crude NMSBA; conversion of NMSBA to NMSBC; reacting cyclohexanedione with 2-nitro-4-methylsulphonyl benzoyl chloride (NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; a distillation step; formation of potassium enolate mesotrione solution; one or more purification steps; and crystallisation of mesotrione.
15. A process for preparing mesotrione, said process comprising: oxidation of NMST to give crude NMSBA,; optional partial purification of crude NMSBA; conversion of NMSBA to NMSBC; reacting cyclohexanedione with 2-nitro-4-methylsulphonyl benzoyl chloride (NMSBC) to form an enol ester followed by a rearrangement process to give mesotrione; formation of a mesotrione enolate solution; decantation, filtration and adsorption treatment carried out in any order; and crystallisation of mesotrione.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0323090A GB0323090D0 (en) | 2003-10-02 | 2003-10-02 | Novel process |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200601864B true ZA200601864B (en) | 2007-07-25 |
Family
ID=29415377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200601864A ZA200601864B (en) | 2003-10-02 | 2006-03-03 | Process for purifying mesotrione |
Country Status (5)
Country | Link |
---|---|
CN (1) | CN100378071C (en) |
GB (1) | GB0323090D0 (en) |
GT (1) | GT200400195A (en) |
UA (1) | UA82722C2 (en) |
ZA (1) | ZA200601864B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100537530C (en) * | 2007-06-08 | 2009-09-09 | 浙江工业大学 | Synthesis process of sulcoatrione |
CN102649774A (en) * | 2012-02-02 | 2012-08-29 | 北京颖泰嘉和生物科技有限公司 | Method of reducing cyanide in sulcotrione |
CN103373946B (en) * | 2012-04-23 | 2015-04-29 | 中国中化股份有限公司 | Method for preparing mesotrione with stable crystal form |
CN103588685B (en) * | 2013-10-18 | 2016-01-13 | 浙江省诸暨合力化学对外贸易有限公司 | Three ketones ammonium salt compound and preparation method thereof and application |
CN103910659B (en) * | 2013-11-04 | 2016-05-11 | 迈克斯(如东)化工有限公司 | Process for purification and the intermediate thereof of 2-nitro-4-methyl sulfonylbenzoic acid |
CN105712912B (en) * | 2014-12-02 | 2017-09-01 | 浙江省诸暨合力化学对外贸易有限公司 | A kind of preparation method of trione compounds and its intermediate |
GB2530838B (en) * | 2015-06-08 | 2020-01-22 | Rotam Agrochem Int Co Ltd | Process for purifying mesotrione |
CN106699616A (en) * | 2016-11-17 | 2017-05-24 | 北京颖泰嘉和生物科技股份有限公司 | Purification method of new 2-nitro-4-methylsulfonylbenzoic acid |
CN110078647B (en) * | 2019-05-15 | 2021-04-13 | 北京颖泰嘉和生物科技股份有限公司 | Post-treatment method of mesotrione reaction product |
CN111440099B (en) * | 2020-04-09 | 2022-01-04 | 利民化学有限责任公司 | Purification method of tembotrione product |
CN111909066B (en) * | 2020-06-24 | 2022-05-31 | 天津大学 | Crystallization treatment method for improving quality of mesotrione product |
CN114671789B (en) * | 2021-10-25 | 2023-11-03 | 上虞颖泰精细化工有限公司 | Method for continuously crystallizing mesotrione |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9725135D0 (en) * | 1997-11-27 | 1998-01-28 | Zeneca Ltd | Chemical process |
AU2002249384B2 (en) * | 2001-03-26 | 2007-06-07 | Syngenta Limited | Purification of 2-nitro-4-methylsulphonylbenzoic acid |
-
2003
- 2003-10-02 GB GB0323090A patent/GB0323090D0/en not_active Ceased
-
2004
- 2004-01-10 UA UAA200604618A patent/UA82722C2/en unknown
- 2004-09-30 GT GT200400195A patent/GT200400195A/en unknown
- 2004-10-01 CN CNB2004800281851A patent/CN100378071C/en active Active
-
2006
- 2006-03-03 ZA ZA200601864A patent/ZA200601864B/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB0323090D0 (en) | 2003-11-05 |
CN1860102A (en) | 2006-11-08 |
CN100378071C (en) | 2008-04-02 |
GT200400195A (en) | 2005-05-02 |
UA82722C2 (en) | 2008-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200601864B (en) | Process for purifying mesotrione | |
CA2663509C (en) | Process for preparing n-alkyl naltrexone halides | |
IL177723A (en) | Method for reducing cyanide level in mesotrione samples | |
CA2537986C (en) | Process for purifying mesotrione | |
US20090048463A1 (en) | Process for the manufacture of iohexol | |
JP2007523171A (en) | Process for the production of lysergic acid | |
JPS6210491B2 (en) | ||
CN106966980A (en) | The preparation method of high-purity Eptazocine intermediate | |
WO2006057778A2 (en) | Process for the purification of benzphetamine hydrochloride | |
JP2697054B2 (en) | Method for producing p-hydroxybenzaldehyde | |
JP2697055B2 (en) | Method for producing p-hydroxybenzaldehyde | |
WO2003007872A2 (en) | Process for the preparation of citalopram hydrobromide | |
JP3084577B2 (en) | Method for producing optically active atrolactic acid and intermediate for production | |
JP2001064275A (en) | Optical resolution of isocoumarin derivative | |
BE560691A (en) | ||
RO114330B1 (en) | Process for preparing erithromycin ethyl-succinate | |
JP2003171326A (en) | Method for producing cyclic dimer of p-isopropenylphenol | |
JPH0435452B2 (en) | ||
JPH10152472A (en) | Production of 4-hydroxy-1,2,2,6,6-pentamethylpiperidine | |
JPH1121265A (en) | Optically resolution of alpha-isopropyl-para-fluorophenylacetic acid |